Search

everythinglearnresearchcommunity

for

Search:↓

Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Hepatitis B virus exposure may be linked to increased risk of alopecia areata.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

The Wnt signaling pathway is not a major factor in the development of keratoacanthoma, a type of skin tumor.

Ruxolitinib treatment may cause eyelash growth.

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.

Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.

The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Exosomes can help promote hair growth and may treat hair loss.

The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

The session covered updates on skin treatments, including radiotherapy, imiquimod, acitretin, JAK inhibitors, and strategies for managing rosacea and preventing surgical infections.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.